Model of Complications of NIDDM: II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia
Article Information
vol. 20 no. 5 735-744
PubMed
Published By
Print ISSN
Online ISSN
History
- Received July 29, 1996
- Accepted October 28, 1996
- Published in print May 1, 1997.
Copyright & Usage
Copyright © 1997 by the American Diabetes Association
Author Information
- Richard C Eastman, MD,
- Jonathan C Javitt, MD,
- William H Herman, MD,
- Erik J Dasbach, PHD,
- Catherine Copley-Merriman, MBA,
- William Maier, PHD,
- Fred Dong,
- Diane Manninen, PHD,
- Arthur S Zbrozek, MBA,
- James Kotsanos, MD,
- Sanford A Garfield, PHD and
- Maureen Harris, PHD
- Division of Diabetes, Endocrinology, Metabolic Diseases Indianapolis, Indiana
- National Institute of Diabetes and Digestive and Kidney Diseases Bethesda, Maryland Department of Opthalmology Indianapolis, Indiana
- Worthen Center for Eye Care Research, Georgetown University, School of Medicine Washington, D.C. Department of Internal Medicine Indianapolis, Indiana
- Division of Endocrinology and Metabolism, University of Michigan, Epidemiology and Outcomes Research Indianapolis, Indiana
- Parke-Davis Inc. Ann Arbor, Michigan Merck Inc. Indianapolis, Indiana
- Bluebell, Pennsylvania Battelle Inc. Indianapolis, Indiana
- Seattle, Washington Bayer Inc. Indianapolis, Indiana
- West Haven, Connecticut Eli Lilly Inc. Indianapolis, Indiana
- Address correspondence and reprint requests to Richard C. Eastman, MD, Director, Division of Diabetes, Endocrinology, and Metabolic Diseases, NIDDK, Building 31, Room 9A16, 31 Center Dr. MSC 2560, National Institutes of Health, Bethesda, MD 20892-2560.
Statistics from Altmetric.com
Article usage
In this Issue
May 1997, 20(5)
Model of Complications of NIDDM: II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia
